TCR-T cells

BIOLOGICAL5 trials

Sponsors

Second Affiliated Hospital of Guangzhou Medical University, Xiaoshun He, Fujian Cancer Hospital, Beijing DCTY Biotech Co.,Ltd., Sun Yat-sen University

Conditions

Colorectal CancerKRAS G12DKRAS G12VLung CancerNonsmall Cell Lung CancerPancreatic CancerRecurrent Hepatocellular CarcinomaSolid Tumor

Early Phase 1

TCR-T Cells for the Treatment NY-ESO-1-positive Advanced Solid Tumors

Not yet recruitingNCT05648994

Fujian Cancer HospitalSolid Tumors

Start: 2022-12-31End: 2026-03-31Target: 30Updated: 2022-12-13

TCR-T Cell Therapy for KRAS Mutation in Advanced Solid Tumors

Not yet recruitingNCT07342738

Sun Yat-sen UniversityKRAS G12D, KRAS G12V, Solid Tumor

Start: 2026-02-01End: 2029-02-01Target: 25Updated: 2026-01-15

Phase 1

TCR-T Cell Immunotherapy of Lung Cancer and Other Solid Tumors

RecruitingNCT03778814

Second Affiliated Hospital of Guangzhou Medical UniversityNonsmall Cell Lung Cancer, Solid Tumor, Adult

Start: 2018-12-01End: 2036-12-30Target: 30Updated: 2024-06-25

TCR-Redirected T Cell Treatment in Patients With Recurrent HBV-related Hepatocellular Carcinoma Post Liver Transplantation

Xiaoshun HeRecurrent Hepatocellular Carcinoma

Start: 2018-03-29End: 2021-12-31Updated: 2020-12-21

A Study of DCTY1102 Injection in Participants With Advanced Solid Tumors

Not yet recruitingNCT07014878

Beijing DCTY Biotech Co.,Ltd.Colorectal Cancer, Lung Cancer, Pancreatic Cancer

Start: 2026-05-01End: 2028-08-01Target: 18Updated: 2026-05-18

Related Papers

Data from HBV-Specific TCR–T Cell Therapy Combining mRNA Electroporation and Lentiviral Transduction: Treatment Regimen for Recurrent HBV-Related HCC after Liver Transplantation

2025-09-15

HBV-Specific TCR–T Cell Therapy Combining mRNA Electroporation and Lentiviral Transduction: Treatment Regimen for Recurrent HBV-Related HCC after Liver Transplantation

Clinical Cancer Research2025-07-241 citations